Aytu Biopharma Inc., a pharmaceutical company specializing in novel therapeutics, has announced the pricing of an upsized public offering of common stock, raising approximately $14.4 million. The offering includes 9,600,000 shares at an effective price of $1.50 per share, with an additional option for underwriters to purchase up to 1,440,000 more shares. The proceeds are intended for general corporate purposes and to support the exclusive commercialization of EXXUA™ (gepirone) extended-release tablets for major depressive disorder in the U.S. The offering is expected to close shortly, pending standard conditions, with Lake Street Capital Markets, LLC serving as the sole book runner.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。